MRI-guided biopsy in the diagnosis of prostate cancer (again)

The results of the so-called PRECISION trial were just published in the New England Journal of Medicine this morning. … READ MORE …

How many men are really benefiting from genome-targeted prostate cancer treatment?

The answer to that question, at present, is that we don’t know — but it’s probably very few indeed compared to all the men who have progressive forms of prostate cancer. … READ MORE …

MRI-targeted biopsies: better than standard biopsies for at least some patients

A new article in this week’s New England Journal of Medicine has just reported the full results of the so-called PRECISION trial of MRI-targeted vs. standard biopsy techniques in the diagnosis of prostate cancer. … READ MORE …

Genetics, genomics, targeted therapy, and the costs of care

A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …

New consensus statement on monitoring for prostate cancer risk after a first, negative biopsy

There has been no really clear and formal guidance available on how to monitor patients for risk of prostate cancer after a first, negative, standard, 12-core, systematic biopsy. New guidance from the American Urological Association (AUA) and the Society of Abdominal Radiology (SAR) may be helpful in addressing this situation. … READ MORE …

Targeted biopsy processes alone are not good enough for accurate diagnosis

A significant number of patients have wanted to believe that, with the coming of targeted biopsies based on multiparametric MRI imaging, the need for “random” systematic biopsies (e.g., standard 10- or 12-core biopsies) would go away. … READ MORE …

“Basket” studies — another new class of clinical trial

Although it has no immediate relevance to the treatment of prostate cancer, it is worth noting that the results of the very first, completed and published “basket” type of clinical trial appear in this week’s issue of the New England Journal of Medicine (NEJM). … READ MORE …